Anika Therapeutics Inc.
-
Extremities
Anika Therapeutics Files Investigational Device Exemption to Initiate Phase III Study to Expand Indication of MONOVISC® to Treat Pain Caused by Osteoarthritis of the Hip
BEDFORD, Mass.–(BUSINESS WIRE)–Anika Therapeutics, Inc., (NASDAQ: ANIK), a leader in products for tissue protection, healing, and repair based on hyaluronic…
Read More » -
Financial
Anika Therapeutics Announces Date of First-Quarter 2015 Financial Results Conference Call
Anika Therapeutics, Inc. (Nasdaq: ANIK) today announced that it plans to issue its first-quarter 2015 financial results after the close of…
Read More »